{"id":928858,"date":"2026-01-20T16:41:30","date_gmt":"2026-01-20T21:41:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/"},"modified":"2026-01-20T16:41:30","modified_gmt":"2026-01-20T21:41:30","slug":"halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/","title":{"rendered":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">Jan. 20, 2026<\/span> \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&#8220;Halozyme&#8221;) today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT \/ 8:30 am ET.<\/p>\n<p>On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update.<\/p>\n<p>Pre-registration of the live call can be accessed via link here: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4599870-1&amp;h=1802727040&amp;u=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4I1205969&amp;a=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4I1205969\" target=\"_blank\" rel=\"nofollow\">https:\/\/registrations.events\/direct\/Q4I1205969<\/a>. The call will also be webcast live through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will be available 15 minutes before the call, please visit Halozyme.com.<\/p>\n<p>\n        <b>About Halozyme<\/b>\n      <\/p>\n<p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE<sup>\u00ae<\/sup> drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE<sup>\u00ae<\/sup> has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.<\/p>\n<p>Halozyme is also developing partner products with Hypercon\u2122 to expand the breadth of its drug delivery technology portfolio. Hypercon\u2122 is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon\u2122 enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon\u2122 technology has been licensed to leading biopharmaceutical partners, including Johnson &amp; Johnson, Eli Lilly, and argenx.<\/p>\n<p>Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex<sup>\u00ae<\/sup> and XYOSTED<sup>\u00ae<\/sup>, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.<\/p>\n<p>Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.<\/p>\n<p>For more information, visit <a href=\"http:\/\/www.halozyme.com\" rel=\"nofollow\">www.halozyme.com<\/a> and connect with us on LinkedIn.<\/p>\n<p>\n        <b>Contacts<\/b>\n      <\/p>\n<p>Tram Bui<br \/>Halozyme<br \/>VP, Investor Relations and Corporate Communications<br \/>609-359-3016<br \/><a href=\"mailto:tbui@halozyme.com\" target=\"_blank\" rel=\"nofollow\">tbui@halozyme.com<\/a><\/p>\n<p>Sydney Charlton<br \/>Teneo<br \/>917-972-8407<br \/><a href=\"mailto:sydney.charlton@teneo.com\" target=\"_blank\" rel=\"nofollow\">sydney.charlton@teneo.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1255\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" title=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" alt=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA67369&amp;sd=2026-01-20\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update-302665875.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update-302665875.html<\/a><\/p>\n<p>SOURCE Halozyme Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA67369&amp;Transmission_Id=202601201605PR_NEWS_USPR_____LA67369&amp;DateId=20260120\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, Jan. 20, 2026 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&#8220;Halozyme&#8221;) today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT \/ 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https:\/\/registrations.events\/direct\/Q4I1205969. The call will also be webcast live through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928858","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Jan. 20, 2026 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&#8220;Halozyme&#8221;) today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT \/ 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https:\/\/registrations.events\/direct\/Q4I1205969. The call will also be webcast live through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will &hellip; Continue reading &quot;Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T21:41:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update\",\"datePublished\":\"2026-01-20T21:41:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/\",\"name\":\"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"datePublished\":\"2026-01-20T21:41:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Jan. 20, 2026 \/PRNewswire\/ &#8212; Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&#8220;Halozyme&#8221;) today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT \/ 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https:\/\/registrations.events\/direct\/Q4I1205969. The call will also be webcast live through the &#8220;Investors&#8221; section of Halozyme&#8217;s corporate website and a recording will be made available following the close of the call. To access the webcast and presentation materials, which will &hellip; Continue reading \"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-20T21:41:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update","datePublished":"2026-01-20T21:41:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/"},"wordCount":483,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/","name":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","datePublished":"2026-01-20T21:41:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-host-investor-conference-call-to-provide-updated-financial-guidance-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928858"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928858\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}